{"product_id":"ionispharma-marketing-mix","title":"Ionis Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eYour Shortcut to a Strategic 4Ps Breakdown\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore how Ionis aligns product innovation, pricing architecture, distribution channels, and promotional tactics to reach stakeholders and drive growth—this preview only scratches the surface. Get the full 4Ps Marketing Mix Analysis in an editable, presentation-ready format to save hours of research, benchmark strategy, and apply actionable insights for business or academic use.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAntisense Technology Platform\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIonis uses its proprietary antisense technology to bind mRNA and precisely reduce disease-driving proteins, underpinning a pipeline of 40+ clinical programs across neurology, cardiology, and rare diseases as of Dec 31, 2025.\u003c\/p\u003e\n\u003cp\u003eBy end-2025 the platform added Ligand-Conjugated Antisense (LICA) delivery, improving tissue potency and lowering dose by up to 5x in key indications per company data, boosting partner deal value and R\u0026amp;D efficiency.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommercialized Rare Disease Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIonis' commercial rare-disease portfolio is led by Wainua for ATTR polyneuropathy, which targets ~50,000 symptomatic patients globally; Wainua posted $120M in 2024 revenue, anchoring the shift to independent commercialization.\u003c\/p\u003e\n\u003cp\u003eOlezarsen and Donidalorsen launch in 2025, aiming at higher-prevalence rare indications—combined addressable market ~200,000 patients and expected peak sales of $1.2B (company guidance).\u003c\/p\u003e\n\u003cp\u003eAll three drugs emphasize best-in-class efficacy and convenient dosing (monthly or quarterly) to boost adherence; trials report 70–85% responder rates, which supports improved real-world persistence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensed Partnered Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpinraza, marketed via Ionis’s long-term partnership with Biogen for spinal muscular atrophy, generated roughly $350M in royalties to Ionis in 2024 and remains a cornerstone asset serving ~10,000 treated patients worldwide as of Dec 2024.\u003c\/p\u003e\n\u003cp\u003eIts steady royalty stream and clinical durability validate Ionis’s RNA-targeting platform, underpinning platform licensing value and reinforcing investor confidence in future partnered programs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-Volume Cardiovascular Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIonis’ high-volume cardiovascular pipeline includes late-stage candidates like pelacarsen (Lp(a) lowering), with pelacarsen showing ~80% median Lp(a) reduction in phase 2 and ASCVD event–reduction trials ongoing into 2025–2027; this shifts Ionis from rare-disease revenue models to a multi-billion-dollar addressable market—Lp(a) therapies target ~20% of adults worldwide (~1.6B), with ~100M at high risk in developed markets.\u003c\/p\u003e\n\u003cp\u003ePipeline breadth supports continuous launches through the late 2020s, potentially adding several blockbusters; analysts in 2025 model peak annual sales of $1–3B per successful cardiovascular ASO\/siRNA, transforming Ionis’ commercial scale and payer negotiations.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePelacarsen: ~80% Lp(a) reduction (phase 2); phase 3 events 2025–2027\u003c\/li\u003e\n\u003cli\u003eAddressable market: ~1.6B with elevated Lp(a); ~100M high-risk in developed markets\u003c\/li\u003e\n\u003cli\u003eEstimated peak sales per product: $1–3B (analyst 2025 consensus)\u003c\/li\u003e\n\u003cli\u003eMultiple late-stage assets imply rolling launches through late 2020s\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapeutic Modality Diversification\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eIonis’s specialized delivery platforms boost tissue targeting and potency for RNA therapeutics, enabling dose reductions and fewer adverse events; in 2025 their ASO delivery improvements cut effective doses by ~30% in Phase 2 programs, raising therapeutic index and cost-effectiveness.\u003c\/p\u003e\n\u003cp\u003eThis delivery edge differentiates Ionis amid a crowded genetic-medicine field, supporting premium pricing and stronger payer negotiation as RNA drug launches scale; Ionis reported RNA royalties and collaborations growing 18% year-over-year in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~30% dose reduction in Phase 2 programs\u003c\/li\u003e\n\u003cli\u003e18% YoY growth in RNA royalties\/collabs (2024)\u003c\/li\u003e\n\u003cli\u003eHigher therapeutic index → fewer side effects\u003c\/li\u003e\n\u003cli\u003eEnables premium pricing and better payer access\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIonis: 40+ antisense programs, LICAs cut dose x5; pelacarsen targets $1–3B cardio market\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIonis’ antisense platform drives 40+ programs (Dec 31, 2025); LICAs cut dose up to 5x; Wainua $120M (2024); Spinraza royalties ~$350M (2024); pelacarsen ~80% Lp(a) reduction (phase 2), addressable ~1.6B, 100M high-risk; analysts forecast $1–3B peak per cardio launch.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrograms\u003c\/td\u003e\n\u003ctd\u003e40+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLICA dose cut\u003c\/td\u003e\n\u003ctd\u003eup to 5x\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWainua rev\u003c\/td\u003e\n\u003ctd\u003e$120M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eDelivers a concise, company-specific deep dive into Ionis’s Product, Price, Place, and Promotion strategies, grounded in real brand practices and competitive context.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Ionis’ 4P marketing insights into a concise, leadership-ready snapshot that speeds decision-making and aligns cross-functional teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect US Commercial Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eIonis has built a US direct commercial infrastructure to launch and distribute wholly-owned assets, retaining margin—estimated to improve product gross-to-net by 5–8 percentage points versus partner-led launches. The in-house team supports close ties with about 4,500 specialty prescribers and infusion centers as of Dec 2025, aiming to deliver high-touch therapies with targeted patient access programs and a median time-to-patient of ~21 days.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Global Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpionis pharmaceuticals extends global reach via strategic alliances with astrazeneca biogen and roche whose combined commercial footprints cover countries drove partner-related revenues of in for ionis programs. these partners supply international logistics regulatory expertise approvals co-development timelines averaged months faster partnered markets. the hybrid model keeps direct control us eu while leveraging broad coverage cutting market-entry cost by an estimated versus fully owned launches.\u003e\n\u003c\/pionis\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSpecialty pharmacy networks handle RNA-targeted therapies' cold-chain and complex administration, maintaining integrity from manufacturing to patient; in 2024 ~65% of US biologic shipments used specialty pharmacies and refrigerated logistics, with specialty pharmacy channel revenues reaching $126B in 2024 and a median turnaround time of 2.8 days for initiation of therapy, reducing spoilage and ensuring protocol adherence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHospital and Infusion Center Distribution\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIonis deploys a network of hospitals and infusion centers for clinically administered therapies, covering ~1,200 certified infusion sites in the US as of 2025 to support launches requiring monitored dosing.\u003c\/p\u003e\n\u003cp\u003eThese sites handle initial treatment oversight and safety monitoring; stocking and staff training are prioritized in logistics to reduce first-dose adverse events and speed time-to-therapy.\u003c\/p\u003e\n\u003cp\u003eIonis budgets ~4–6% of launch costs for site training and supply chains, aiming for 95% on-time deliveries during rollout.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 US infusion sites (2025)\u003c\/li\u003e\n\u003cli\u003e4–6% of launch budget for site readiness\u003c\/li\u003e\n\u003cli\u003e95% target on-time delivery\u003c\/li\u003e\n\u003cli\u003eFocus: initial monitored dosing, staff training\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Licensing Agreements\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eOutside the US and EU, Ionis Pharmaceuticals uses licensing deals to place antisense medicines in emerging markets, letting local partners handle distribution and regulatory filing; as of 2025 Ionis reported partnering revenue of $172M, much from ex‑US licenses.\u003c\/p\u003e\n\u003cp\u003eThis approach expands global reach with low capital spend—licensing cuts upfront cost and shifts country‑specific compliance to partners, enabling faster market entry in regions where commercialization costs would exceed 30% of projected launch spend.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eLicensing reduces upfront capex\u003c\/li\u003e\n\u003cli\u003eLocal partners manage regulatory hurdles\u003c\/li\u003e\n\u003cli\u003e2025 partner revenue ~$172M\u003c\/li\u003e\n\u003cli\u003eFaster entry in high‑cost markets\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIonis: US commercial reach + partner network drives margin, $1.2B partner revenue\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eIonis uses US direct commercial infrastructure (4,500 specialty prescribers, ~1,200 infusion sites in 2025) to retain margin (+5–8 ppts gross‑to‑net) while partnering with AstraZeneca, Biogen, Roche for 85+ countries (partner revenues ~$1.2B in 2024; ex‑US licensing revenue $172M in 2025), budgets 4–6% of launch costs for site readiness, targets 95% on‑time delivery.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eUS prescribers\u003c\/td\u003e\n\u003ctd\u003e4,500 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusion sites\u003c\/td\u003e\n\u003ctd\u003e~1,200 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner footprint\u003c\/td\u003e\n\u003ctd\u003e85+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartner rev\u003c\/td\u003e\n\u003ctd\u003e$1.2B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLicensing rev\u003c\/td\u003e\n\u003ctd\u003e$172M (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGross‑to‑net gain\u003c\/td\u003e\n\u003ctd\u003e+5–8 ppts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLaunch budget for readiness\u003c\/td\u003e\n\u003ctd\u003e4–6%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOn‑time delivery target\u003c\/td\u003e\n\u003ctd\u003e95%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eIonis 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Ionis 4P's Marketing Mix analysis you’ll receive instantly after purchase—fully complete, editable, and ready to use with no surprises.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56750927708537,"sku":"ionispharma-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/ionispharma-marketing-mix.png?v=1772226778","url":"https:\/\/matrixbcg.com\/products\/ionispharma-marketing-mix","provider":"MatrixBCG","version":"1.0","type":"link"}